Investigating Clinical Heterogeneity in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

Immune checkpoint inhibitors (ICI) can cause immune related adverse events like inflammatory arthritis (ICI-IA). ICI-IA is a new and impactful condition, but there is limited understanding of pathogenesis, natural history, and response to treatments. The study will have two main goals. 1. Evaluate efficacy of steroid sparing immunosuppression and determinants of ICI-IA persistence. 2. Identify biomarkers that predict ICI-IA disease severity and initial treatment-associated response. These questions will be answered using the RADIOS cohort, a prospective cohort of patients with rheumatic immune related adverse events due to ICI therapy.

NCT Number	NCT07737535
Lead Sponsor	Johns Hopkins University Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions	Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Enrollment	1,000 participants
Start Date	2026-07-01
Primary Completion	2031-07-01 (estimated)
Study Completion	2031-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-30